Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
16.84
-0.87 (-4.91%)
At close: Apr 1, 2025, 4:00 PM
17.00
+0.16 (0.95%)
After-hours: Apr 1, 2025, 7:56 PM EDT
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
314.28M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TECX News
- 12 days ago - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data - Seeking Alpha
- 2 months ago - Tectonic Announces $185 Million Private Placement - GlobeNewsWire
- 2 months ago - Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF - GlobeNewsWire
- 3 months ago - Tectonic Therapeutic: Protein Engineering Platform For GPCRs - Seeking Alpha
- 4 months ago - Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 - GlobeNewsWire
- 4 months ago - Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - GlobeNewsWire
- 5 months ago - Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein - GlobeNewsWire